Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion.
In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much than anything before ESMO25 pCR> 50% questions unselected surgery.”
“This becomes standard of care here.
Questions-How would this perform in a cisplatin eligible population? Better? Can ctDNA help?
How many cycles are needed? B15 & VOLGA can help here.
Finally, bladder sparing trials are needed to address the need for surgery.”
You can also read.
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
